805 research outputs found
Direct oral anticoagulants halve thromboembolic events after cardioversion of AF compared with warfarin
No full text
Incremental Nonlinear Dynamic Inversion Control with Flight Envelope Protection for the Flying-V
No full textTo reduce the environmental impact of aircraft, technological innovations are required. The Flying-V could be one of these technical innovations, as research shows it could be up to 20 % more efficient than regular aircraft of the same size. The Flying-V however has low lateral control authority, and pitchbreak-up could occur for high angles of attack.The goal of this research is to increase the maturity of the Flight Control System of the Flying-V. To do so, a Flight Control Systems (FCS) is proposed with Flight Envelope Protection, which is based on an Incremental Nonlinear Dynamic Inversion inner loop control law. For longitudinal control, a 𝐶* control law was implemented, and for lateral control, a Rate Control Attitude Hold control law. To test the performance of this controller, the handling qualities of this FCS were determined in the presence of sensor dynamics, as well as discretization effects. The controller is able to be tuned within level 1 handling qualities at selected design conditions, as long as the time delay of the angular rate sensorsis no more than 0.04 seconds.The effect of sampling time and aerodynamic uncertainties were also evaluated for cruise conditions, and it was shown that the controller is robust for changes in the aerodynamic model, as well as being statically stable for sampling times lower than 0.1 seconds. Finally, the Flight Envelope Protection laws were tested, and shown to meet the requirements, for the cases that were tested, setting a step in maturity for the Flight Control SystemAerospace Engineering | Control & Simulatio
Incremental Nonlinear Dynamic Inversion control with Flight Envelope Protection for the Flying-V
No full textTo reduce the impact of aviation on the environment, technological innovations, such as the Flying-V are required. The Flying-V is a proposed commercial flying wing, which uses the Airbus A350-900 as reference aircraft. In this work, a Flight Control system for the Flying-V is proposed with a longitudinal ��∗ control law, and a Rate Control Attitude Hold roll control law. This Flight Control System also includes a Flight Envelope Protection law to prevent reaching angles of attack higher than 30 degrees, where the Flying-V becomes statically unstable. The FEP also prevents the Flying-V from reaching load factors above 2.5 and limits the roll angle. The control laws are tuned to be within level 1 handling qualities in the selected approach and cruise conditions, with the presence of sensor dynamics, and a digital control system. Robustness for aerodynamic uncertainties is also shown. Finally, it is shown that the FEP is able to prevent the angle of attack from becoming too large.Control & Simulatio
Intentions And Information In Discourse
No full textThis paper is about the flow of inference between communicative intentions, discourse structure and the domain during discourse processing. We augment a theory of discourse interpretation with a theory of distinct mental attitudes and reasoning about them, in order to provide an account of how the attitudes interact with reasoning about discourse structure. INTRODUCTION The flow of inference between communicative intentions and domain information is often essential to discourse processing. It is well reflected in this discourse from Moore and Pollack (1992): (1)a. George Bush supports big business. b. He's sure to veto House Bill 1711. There are at least three different interpretations. Consider Context 1: in this context the interpreter I believes that the author A wants to convince him that (1b) is true. For example, the context is one in which I has already uttered Bush won't veto any more bills. I reasons that A's linguistic behavior was intentional, and therefore that A believ..
A decade of Australian general practice activity 2002–03 to 2011–12
No full textThis book presents ten years of data from the BEACH (Bettering the Evaluation and Care of Health) program, and reports changes that have occurred over the decade 2002–03 to 2011–12, in the characteristics of GPs and the patients they see, the problems they manage and the treatments they provide. A companion report, General practice activity in Australia 2011–12, describes the 2011–12 annual results in more detail, available at .1 BEACH is a continuous cross-sectional national study that began in April 1998.
Every year each of about 1,000 randomly selected GPs records details of 100 consecutive encounters on structured paper recording forms, and provides information about themselves and their practice. The database now holds data for 1.38 million records from 13,815 participating GPs.
*Other authors - Joan Henderson, Lisa Valenti, Christopher Harrison, Carmen Zhang, Timothy Chambers, Allan J Pollack, Clare Bayram, Julie O’Halloran, Ying Pan.
 
New Functional Imaging Technology to Differentiate between Chronic Obstructive Pulmonary Disease and Heart Failure
No full text[West J Emerg Med. 2011;12(1):17-18.
Evidence Supporting Idarucizumab for the Reversal of Dabigatran
No full textAbstractIdarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran. It has demonstrated prompt and durable reversal of the anticoagulant effects of dabigatran in animal studies and phase 1 studies of young, elderly, and renally impaired volunteers. Although elective invasive procedures and most bleeding complications in dabigatran-treated patients can be managed by temporarily stopping dabigatran therapy and using supportive measures, there are rare clinical situations that require urgent reversal of the anticoagulant effect of dabigatran. The effectiveness and safety of 5 g of intravenous idarucizumab is being investigated in a prospective, open-label, single-cohort study in patients with serious bleeding or in those requiring an urgent procedure. In an interim analysis of the first 90 participants, idarucizumab rapidly and completely reversed the anticoagulant activity of dabigatran in 88%-98% of participants, and there were no safety concerns, with no deaths or serious adverse events being attributable to idarucizumab. Supported by these interim results, idarucizumab has been approved in the United States and the European Union for use when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in patients with life-threatening or uncontrolled bleeding. Clinical use of idarucizumab should follow the same processes as patient enrollment in this study, which is projected to be completed in 2016. The outcomes achieved with this specific reversal agent are likely to be of continued interest to treating physicians
- …
